The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...
Tatiana Schlossberg, the youngest granddaughter of President John F. Kennedy, recently revealed she was diagnosed with terminal acute myeloid leukemia (AML) due to a rare genetic anomaly. In a ...
Researchers have led a global study that identified molecular predictors of survival among Black patients with acute myeloid leukemia (AML). The study suggests a need to modify current AML risk layers ...
University of Cincinnati Cancer Center experts will present abstracts at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Dec. 7-10 in San Diego. Trial finds AML drug is ...
NPM1-mutated AML prognosis was refined using a new genetic model integrating co-mutations, improving risk classification and ...
Molecular lesion data in LR-MDS prognostic models reduce the significance of traditional parameters like bone marrow blast percentage. Molecular data altered risk stratification for 30% of patients, ...
Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more ...
– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML – – FLT3 mutations occur in approximately 30% of ...
What Is Ziftomenib, and Why Does It Matter? Ziftomenib, sold under the brand name Komzifti, is a new oral medicine approved to treat adults with a type of blood cancer called acute myeloid leukemia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results